These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 12548045)

  • 1. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
    Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
    Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
    Randolph GW; Daniels GH
    Thyroid; 2002 Nov; 12(11):989-96. PubMed ID: 12490076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
    Bal CS; Kumar A; Pant GS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
    Hoyes KP; Owens SE; Millns MM; Allan E
    Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?
    Dietlein M; Luyken WA; Schicha H; Larena-Avellaneda A
    Nucl Med Commun; 2005 Jan; 26(1):3-8. PubMed ID: 15604941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
    Logue JP; Tsang RW; Brierley JD; Simpson WJ
    Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
    Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
    Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
    Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
    Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma.
    Arad E; O'Mara RE; Wilson GA
    Clin Nucl Med; 1993 Aug; 18(8):662-3. PubMed ID: 8403696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
    Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
    Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
    O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
    Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
    Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
    Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
    Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.